8-K: BioLargo Revokes Pooph License Over $3.8M Unpaid Dues

BioLargo, Inc. has revoked its exclusive license to Pooph Inc. and terminated their agreements due to Pooph's failure to pay approximately $3.8 million in royalties and product invoices, leading to a potential substantial asset impairment.

Summary

• BioLargo, Inc. and its wholly owned subsidiary, ONM Environmental, Inc., revoked the exclusive, royalty-bearing license granted to Pooph Inc.
• The revocation and termination of the License Agreement and Preferred Master Manufacturing Agreement (PMMA) are due to Pooph's failure to pay royalties and product invoices.
• Pooph owes BioLargo $1,378,141 in past due royalties and $2,385,468 on product invoices, totaling approximately $3.8 million.
• The PMMA was amended on June 6, 2025, to allow Pooph to pay these past due amounts through a weekly payment plan with 10% interest, maturing July 3, 2026.
• BioLargo delivered notice on September 24, 2025, that the license grant was immediately revoked and the License Agreement terminated with 150 days notice.
• Pooph is no longer allowed to market or sell products that incorporate, use, or are based on BioLargo's patents and proprietary information.
• Pooph indicated on September 19, 2025, that it is developing an independent formula, will no longer order from BioLargo, and will not accrue future royalty obligations, while also terminating the PMMA citing BioLargo's refusal to deliver products.
• BioLargo disputes Pooph's claim, stating it withheld product due to Pooph's failure to meet weekly payment plan terms, and believes Pooph's PMMA termination is a breach of contract.
• BioLargo management is considering a substantial impairment of a $3,486,000 note receivable from Pooph on its balance sheet as of June 30, 2025.

Sentiment

Score: 3

Explanation: The termination of a significant licensing agreement and the expectation of a substantial asset impairment due to unpaid dues are significant negative events. While management expresses confidence in other ventures, the immediate financial impact and loss of a validated market channel are concerning.

Positives

• BioLargo remains committed to advancing its broad portfolio of technologies, products, and services in infection control, wound care, PFAS contamination, and battery systems.
• The company is steadfast in protecting its intellectual property and expanding its proven odor-control technology into new markets.
• BioLargo's science has been validated in the marketplace at scale, with Pooph products reaching over $50 million in annual sales powered by BioLargo's technology.
• Management expresses confidence in the strength of its technology and significant opportunities ahead despite the relationship termination.

Negatives

• Termination of a material definitive agreement (License Agreement and PMMA) with Pooph Inc.
• Pooph failed to pay approximately $3.8 million in royalties and product invoices.
• BioLargo expects a substantial impairment of a $3,486,000 note receivable from Pooph.
• Loss of future royalty income and product sales from Pooph.
• Pooph is independently developing a new formula, indicating a complete separation and loss of a significant customer/licensee.
• Potential for legal disputes over breach of contract claims.

Risks

• Potential for substantial impairment of the $3,486,000 note receivable from Pooph Inc.
• Legal and financial risks associated with the breach of contract claims against Pooph Inc.
• Loss of revenue stream from Pooph Inc. and the need to find new partners or direct sales channels for its odor-control technology.
• The effect of regional economic conditions on the company's business, including effects on purchasing decisions by consumers and businesses.
• The ability of the company to compete in markets that are highly competitive and subject to rapid technological change.
• The ability of the company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis.
• The dependency of the company on the performance of distributors of the company's products.

Future Outlook

BioLargo remains committed to advancing its broad portfolio of technologies, products, and services, focusing on infection control, wound care, PFAS contamination, and innovative battery systems. The company plans to protect its intellectual property and expand its odor-control technology into new markets, confident in its technology's strength and future opportunities.

Management Comments

• "Our science has been validated in the marketplace at scale." Dennis P. Calvert, CEO of BioLargo.
• "While we regret the outcome of this relationship, we remain confident in the strength of our technology and the significant opportunities ahead." Dennis P. Calvert, CEO of BioLargo.
• "Our duty is to our shareholders, our partners, and the integrity of our work—and we will continue to build on this proven success." Dennis P. Calvert, CEO of BioLargo.

Industry Context

This event highlights the challenges in licensing agreements within the cleantech and consumer product sectors, particularly when dealing with intellectual property and payment terms. While BioLargo's technology enabled a brand like Pooph to achieve significant market penetration ($50M annual sales), the termination underscores the importance of robust contractual enforcement and the risks associated with relying on a single major licensee. The company's pivot to focus on other technologies (PFAS, water treatment, batteries) is consistent with broader cleantech trends seeking diverse revenue streams and addressing critical environmental issues.

Legal Proceedings

• BioLargo believes Pooph's termination of the PMMA is a breach of contract, among others.
• BioLargo has revoked the license and terminated the agreement due to Pooph's failure to pay contractual obligations.

Stakeholder Impact

• Shareholders: Negative impact due to loss of revenue, potential asset impairment, and uncertainty regarding recovery of owed funds. Potential for stock price decline.
• Employees: No direct impact mentioned, but overall company financial health could indirectly affect employees.
• Customers (of Pooph): May experience changes in product formulation or availability as Pooph develops its own formula and stops using BioLargo's technology.
• Creditors (of BioLargo): Potential concern over the impairment of a significant receivable and loss of a revenue stream.

Next Steps

• BioLargo management to determine the fair value impairment of the note receivable from Pooph Inc.
• BioLargo will continue to protect its intellectual property.
• BioLargo will continue to advance its broad portfolio of technologies, products, and services in infection control, wound care, PFAS contamination, and innovative battery systems.
• BioLargo will expand the reach of its proven odor-control technology into new markets.
• Pooph Inc. must immediately stop marketing and selling products based on BioLargo's proprietary information unless the license is reinstated.
• Pooph Inc. will continue submitting royalty reports for sales of remaining inventory purchased from BioLargo.
• Potential legal actions by BioLargo against Pooph Inc. for breach of contract.

Key Dates

Recommendation

The termination of a material licensing agreement with a key partner, coupled with a substantial unpaid debt of approximately $3.8 million and the expectation of a significant asset impairment ($3.486 million note receivable), represents a severe negative financial event for BioLargo. While the company highlights other technologies, the immediate loss of a validated revenue stream and the financial hit from the unpaid amounts are highly detrimental. The uncertainty surrounding the recovery of these funds and potential legal costs further compounds the risk. This situation significantly weakens the company's financial position and future revenue outlook, warranting a "sell" recommendation for a seasoned investor.

Keywords

BioLargo, BLGO, Pooph, license revocation, contract termination, intellectual property, unpaid royalties, asset impairment, cleantech, odor control, SEC filing, 8-K, financial reporting, breach of contract